Knowledge Hub

Approach to investigating Blood Culture-Negative Endocarditis (BCNE)

PathCare introduces a new multiplex PCR panel to detect Tick-Borne pathogens

Optimising Clostridioides difficile Diagnosis

Stool samples sent for C. difficile testing at the reference laboratory in Cape Town, Pathcare will perform routine two-step testing following a positive C. difficile detection on stool PCR testing.

Malaria Update

Recent heavy rainfall across South Africa has led to a continued rise in Malaria cases

Respiratory Pathogen Statistics 2025 Summary

This report is a summary of the results obtained from various molecular respiratory panels performed across PathCare laboratories during 2025

Launch of Salivary Cortisol & Cortisone via LC-HRMS

PathCare will now offer simultaneous measurement of salivary cortisol and cortisone using liquid chromatography–high-resolution mass spectrometry (LC-HRMS).

MOLECULAR SUBTYPING OF ENDOMETRIAL CARCINOMA

Molecular subtyping can assist with predicting treatment outcomes and prognosis of early endometrial cancer and is recommended by the National Comprehensive Cancer Network (NCCN) guidelines.

Respiratory Pathogen Statistics September 2025

This report is a summary of the results obtained from various molecular respiratory panels performed across PathCare laboratories during September 2025

Gastro-Intestinal Pathogen Statistics

Laboratory-based data for all GIT molecular panels requested for patients at PathCare laboratories nationally, for the period June to August 2025, are presented in this report.

The value of therapeutic drug monitoring of linezolid in clinical practice

Linezolid, a synthetic oxazolidinone antibiotic, is frequently used for the treatment of serious gram-positive infections including Staphylococcus aureus and enterococci.

With regard to Designated Service Provider (DSP) Contracts the following law is pertinent for service providers who are not a DSP:

  1. In terms of Section 59 (2) of the Medical Schemes Act 131 of 1998 the medical scheme must pay valid invoices within 30 days of receipt thereof or advise both the member and service provider of reasons why the invoice is not valid and provide the opportunity to correct the invoice.
  2. Where services are in respect of medical emergencies or involuntarily obtained services for PMB conditions, the scheme has to pay for the full cost of the services provided without deduction or co-payment or limiting the tariff amount. (Regulation 8 (1) of the Medical Schemes Act no. 131 of 1998.)
  3. DOH notice 214 of 2021 requires that a scheme pays for services provided at the same rate and in terms of the same rules as they pay their DSPs in respect of services voluntarily obtained, whether they are PMBs or not.
  4. The process followed in respect of appointing a DSP is required to be fair, equitable, transparent, competitive or cost effective as required in terms of Notice 214 of the DOH.

In summary:

  1. The law protects the patient’s choice to use their laboratory of choice, even if it is not a DSP, and the scheme is still obliged to reimburse us at the scheme rate for valid claims.
  2. This is true for PMB conditions as well as non-PMB conditions.
  3. The medical scheme must pay valid invoices within 30 days or advise both the member and service provider of reasons why the invoice is not valid and provide the opportunity to correct invoice.
  4. A scheme must pay for the services provided at a tariff not less than what they would pay a DSP.
  5. Should any patient have a valid claim rejected because we are not a DSP, we can assist.

 

Bacterial Vaginosis

Bacterial vaginosis (BV) is the most common cause of vaginal discharge in women. It is characterised by a dysbiosis of the normal vaginal flora whereby a mixed bacterial flora including mixed anaerobes replaces the dominant lactobacilli.

read more